These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16871570)

  • 41. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
    Shiffman ML; Ghany MG; Morgan TR; Wright EC; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Gretch DR
    Gastroenterology; 2007 Jan; 132(1):103-12. PubMed ID: 17241864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
    Dore GJ; Torriani FJ; Rodriguez-Torres M; Bräu N; Sulkowski M; Lamoglia RS; Tural C; Clumeck N; Nelson MR; Mendes-Correa MC; Godofsky EW; Dieterich DT; Yetzer E; Lissen E; Cooper DA
    AIDS; 2007 Jul; 21(12):1555-9. PubMed ID: 17630550
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol].
    Pivert A; Payan C; Lunel F;
    Pathol Biol (Paris); 2004 Nov; 52(9):522-8. PubMed ID: 15531116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Presence of HCV RNA in peripheral blood mononuclear cells may predict patients response to interferon and ribavirin therapy.
    Zaman N; Asad MJ; Raza A; Raja GK; Akhter S; Mahmood M; Mahmood RT
    Ann Saudi Med; 2014; 34(5):401-6. PubMed ID: 25827697
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.
    Roberts S; Gordon A; McLean C; Pedersen J; Bowden S; Thomson K; Angus P
    Clin Gastroenterol Hepatol; 2007 Aug; 5(8):932-7. PubMed ID: 17544878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
    Halfon P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Perronne C; Pol S; Cacoub P
    Antivir Ther; 2009; 14(2):211-9. PubMed ID: 19430096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
    Zarski JP; Sturm N; Desmorat H; Melin P; Raabe JJ; Bonny C; Sogni P; Pinta A; Rouanet S; Babany G; Cheveau A; Chevallier M
    Liver Int; 2010 Aug; 30(7):1049-58. PubMed ID: 20492512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.
    Lee HS; Kweon YO; Tak WY; Park SY; Kang EJ; Lee YL; Yang HM; Park HW
    Clin Mol Hepatol; 2013 Jun; 19(2):148-55. PubMed ID: 23837139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.
    Bonkovsky HL; Snow KK; Malet PF; Back-Madruga C; Fontana RJ; Sterling RK; Kulig CC; Di Bisceglie AM; Morgan TR; Dienstag JL; Ghany MG; Gretch DR;
    J Hepatol; 2007 Mar; 46(3):420-31. PubMed ID: 17196293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Follow-up of patients with chronic hepatitis C and a sustained viral response.
    Serfaty L
    Liver Int; 2016 Jan; 36 Suppl 1():67-71. PubMed ID: 26725900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy.
    Ogawa E; Furusyo N; Murata M; Hayashi T; Shimizu M; Mukae H; Toyoda K; Hotta T; Uchiumi T; Hayashi J
    Antiviral Res; 2016 Feb; 126():35-42. PubMed ID: 26692214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay.
    Gourlain K; Soulier A; Pellegrin B; Bouvier-Alias M; Hézode C; Darthuy F; Rémiré J; Pawlotsky JM;
    J Clin Microbiol; 2005 Apr; 43(4):1669-73. PubMed ID: 15814982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.
    van Tilborg M; Al Marzooqi SH; Wong WWL; Maan R; Vermehren J; Maasoumy B; Mazzulli T; Bolotin S; Garber G; Guerra F; Flud CR; Kowgier M; Janssen HL; de Knegt RJ; Pawlotsky JM; Cloherty GA; Duarte-Rojo A; Sarrazin C; Wedemeyer H; Feld JJ
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):856-864. PubMed ID: 30274834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comprehensive hepatitis C viral kinetic model explaining cure.
    Snoeck E; Chanu P; Lavielle M; Jacqmin P; Jonsson EN; Jorga K; Goggin T; Grippo J; Jumbe NL; Frey N
    Clin Pharmacol Ther; 2010 Jun; 87(6):706-13. PubMed ID: 20463660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection.
    Halfon P; Bourlière M; Pénaranda G; Khiri H; Ouzan D
    J Clin Microbiol; 2006 Jul; 44(7):2507-11. PubMed ID: 16825372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long term changes in liver histology following treatment of chronic hepatitis C virus.
    Shiffman ML; Sterling RK; Contos M; Hubbard S; Long A; Luketic VA; Stravitz RT; Fuchs M; Sanyal AJ
    Ann Hepatol; 2014; 13(4):340-9. PubMed ID: 24927604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance.
    Sarrazin C
    J Clin Virol; 2002 Dec; 25 Suppl 3():S23-9. PubMed ID: 12467774
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is the benefit of treating patients with cirrhosis proven?
    Bruno S; Boccaccio V; Russo ML; Maisonneuve P
    Liver Int; 2016 Jan; 36 Suppl 1():21-7. PubMed ID: 26725893
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biopsy Specimens From Allograft Liver Contain Histologic Features of Hepatitis C Virus Infection After Virus Eradication.
    Whitcomb E; Choi WT; Jerome KR; Cook L; Landis C; Ahn J; Te HS; Esfeh J; Hanouneh IA; Rayhill SC; Gibson W; Plesec T; Koo J; Wang HL; Hart J; Pai RK; Westerhoff M
    Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1279-1285. PubMed ID: 28501538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.